— Presentation on December 1, 2015, at 2:00 p.m. ET —
BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 16, 2015--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing desensitization treatments for food allergies, today
announced that it will present at the Piper Jaffray 27th Annual
Healthcare Investor Conference in New York City.
About the Presentation
Tuesday, December 1, 2015, at 2:00 p.m. Eastern Time
The live audio webcast of the presentation can be accessed from the
Investor Relations section of the company’s website at www.aimmune.com.
A replay will be available for 14 days following the presentation.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research
Corporation (ARC), is a clinical-stage biopharmaceutical company
developing treatments for peanut allergy and other food allergies.
Aimmune Therapeutics’ characterized oral desensitization immunotherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized product candidates with gradual, controlled
up-dosing protocols to obtain clinically meaningful desensitization to
food allergens. Aimmune Therapeutics plans to initiate enrollment in a
Phase 3 study of its lead product, AR101, a complex mixture of natural
peanut proteins and pharmaceutical-grade ingredients for the treatment
of peanut allergy, one of the most common food allergies, at the
beginning of 2016. For more information, please see www.aimmune.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151116005351/en/
Source: Aimmune Therapeutics, Inc.
Aimmune Therapeutics, Inc.
Amy Figueroa, 650-352-1039